美罗培南和亚胺培南治疗急性白细胞减少期并发肺部感染的成本-效果分析

Meropenem and Imipenem for Acute Aleucocytosis Complicating Pulmonary Infection: Cost-Effectiveness Analysis

目的:评价美罗培南和亚胺培南治疗急性白细胞减少期并发肺部感染的成本-效果。方法:采用回顾性方法,对67例分别采用美罗培南和亚胺培南治疗急性白细胞减少期并发肺部感染的效果进行成本-效果分析。结果:美罗培南组与亚胺培南组的成本分别为3 639.00、6 664.00元;有效率分别为85.29%、90.91%(P>0.05);成本-效果比分别为4 266.62、7 331.21,亚胺培南组相对于美罗培南组的增量成本-效果比为53 839.86。结论:美罗培南治疗急性白血病粒细胞减少期并发肺部感染有明显的药物经济学优势。

OBJECTIVE： To evaluate the cost- effectiveness of meropenem and imipenem for acute aleucocytosis complicating pulmonary infection .METHODS：A cost- effectiveness analysis was performed retrospectively on 67 patients with acute aleucocytosis complicating pulmonary infection treated with meropenem or imipenem.RESULTS： The cost, effective rate and cost- effectiveness ratio of meropenem group vs.imipenem group were 3 639.00 vs. 6 664.00yuan, 85.29% vs.90.91% （P 0.05） and 4 266.62 vs.7 331.21, respectively.The incremental cost effectiveness ratio of the imipenem group as against the meropenem group was 53 839.86.CONCLUSION： Meropenem has marked pharmacoeconomics advantage over imipenem for acute aleucocytosis complicating pulmonary infection.